+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neurological Biomarkers Market Size, Share & Trends Analysis Report by Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), Type, End-use, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 120 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 5450236
Description Jump to:
The global neurological biomarkers market size is expected to reach USD 18.75 billion by 2030, expanding at a CAGR of 12.89% from 2024 to 2030. Increased funding for R&D of neurological biomarkers to boost development of new drugs is expected to impel market growth. National Institute of Neurological Disorders and Stroke provides funding opportunities such as cooperative agreements & development grants for researchers conducting studies related to clinical validation, analytical validation, & biomarker discovery.

Biomarkers play a significant role in the development of drugs for the treatment of neurological diseases. In recent years, there has been a significant rise in investments in the R&D of treatments for neurological diseases. For instance, in December 2020, Target ALS-a nonprofit research foundation-announced research funding of USD 15 million for a project focused on the discovery of novel biomarkers for ALS, which is anticipated to accelerate market growth in the forecast period.

Availability of technologically advanced products such as Quanterix Simoa (single-molecule array), which is a digitized ELISA test with a high signal-to-noise ratio. This technology helps overcome blood-brain barrier issues associated with neurological disease-related biomarkers. Such technological advancements are expected to drive market growth. For instance, in January 2021, Abbott introduced the first rapid blood test for traumatic brain injury, including concussion. This test measures a particular protein that is found in the blood after a traumatic brain injury and can be used to rule out the need for CT scanning in case of negative test results.

Factors such as lack of awareness about such diagnostic products & their high cost and limited availability or absence of neurologists, especially in developing & underdeveloped countries, could affect the adoption of such biomarker-based diagnostic solutions. According to a World Federation of Neurology survey of 63/84 WHO member countries, the majority of neurologists in 31/63 countries worked in major cities. One neurologist was serving a population of about 6,240 to 4,750,000.

Neurological Biomarkers Market Report Highlights

  • In 2023, proteomic type accounted for the largest market share and is anticipated to maintain their dominance over the forecast period as these are essential for accurate diagnosis of disease onset and progression due to the careful detection of posttranslational modifications and protein signatures
  • Parkinson’s disease segment held the largest market share owing to rising incidence and increasing R&D activities.
  • Based on end use, the research organizations and others segment dominated the neurological biomarkers market. Research organizations collaborating for the development of therapeutics for treating neurological disorders utilize biomarkers for assessing the drug tolerance.
  • North America dominated the market owing to presence of market players with strong presence in the U.S. & Canada, and increasing government funding for the development of novel biomarkers
  • Asia-Pacific is anticipated to witness significant growth over the forecast period owing to high adoption of technologically advanced diagnostic products in developed countries such as Japan & Australia and increasing adoption of these products in developing economies such as China and India.

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation And Scope
1.1.1 Segment Definition
1.1.1.1 Application Segment
1.1.1.2 Type Segment
1.1.1.3 End Use Segment
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective - 2
1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Internal database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List Of Abbreviations
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Application And Type Snapshot
2.3 End Use Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Neurological Biomarkers Market Variables, Trends, And Scope
3.1 Neurological Biomarkers Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration And Growth Prospect Mapping
3.3 Pipeline Analysis
3.3.1 Alzheimer’s Disease
3.3.2 Parkinson’s Disease
3.3.3 Multiple Sclerosis
3.3.4 Autism Spectrum Disorder
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Increasing Prevalence Of Neurological Diseases
3.4.1.2 Technological Advancements
3.4.1.3 Increased Funding For R&d In Biomarkers
3.4.2 Market Restraint Analysis
3.4.2.1 Lack Of Consumer Awareness
3.4.2.2 Reimbursement Policies
3.5 Neurological Biomarkers: Market Analysis Tools
3.5.1 Industry Analysis - Porter’s Five Forces
3.5.2 Pestle Analysis
Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2018-2030 (USD Million)
4.1 Neurological Biomarkers Market: Type Movement Analysis
4.1.1 Genomic
4.1.1.1 Genomic Neurological Biomarkers Market, 2018-2030 (USD Million)
4.1.2 Proteomic
4.1.2.1 Proteomic Neurological Biomarkers Market, 2018-2030 (USD Million)
4.1.3 Metabolomic
4.1.3.1 Metabolomic Neurological Biomarkers Market, 2018-2030 (USD Million)
4.1.5 Imaging
4.1.5.1 Imaging Neurological Biomarkers Market, 2018-2030 (USD Million)
4.1.6 Others
4.1.6.1 Other Neurological Biomarkers Market, 2018-2030 (USD Million)
Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2018-2030 (USD Million)
5.1 Neurological Biomarkers Market: Application Movement Analysis
5.1.1 Alzheimer’s Disease
5.1.1.1 Alzheimer’s Disease Market, 2018-2030 (USD Million)
5.1.2 Parkinson’s Disease
5.1.2.1 Parkinson’s Disease Market, 2018-2030 (USD Million)
5.1.3 Multiple Sclerosis
5.1.3.1 Multiple Sclerosis Market, 2018-2030 (USD Million)
5.1.4 Autism Spectrum Disorder
5.1.4.1 Autism Spectrum Disorder Market, 2018-2030 (USD Million)
5.1.5 Others
5.1.5.1 Others Market, 2018-2030 (USD Million)
Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End-use, 2018-2030 (USD Million)
6.1 Neurological Biomarkers Market: End-use Movement Analysis
6.1.1 Hospital & Hospital Laboratories
6.1.1.1 Hospitals & Hospital Laboratories Market, 2018-2030 (USD Million)
6.1.2 Independent Clinical Diagnostic Centers
6.1.2.1 Independent Clinical Diagnostic Centers Market, 2018-2030 (USD Million)
6.1.3 Research Organizations And Others
6.1.3.1 Research Organizations And Others Market, 2018-2030 (USD Million)
Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2018-2030 (USD Million)
7.1 Regional Market Snapshot
7.2 North America
7.2.1 North America Neurological Biomarkers Market, 2018-2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Neurological Biomarkers Market, 2018-2030 (USD Million)
7.2.2.2 Key Country Dynamics
7.2.2.3 Regulatory Framework
7.2.2.4 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Canada Neurological Biomarkers Market, 2018-2030 (USD Million)
7.2.3.2 Key Country Dynamics
7.2.3.3 Regulatory Framework
7.2.3.4 Reimbursement Scenario
7.3 Europe
7.3.1 Europe Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.2 UK
7.3.2.1 UK Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.2.2 Key Country Dynamics
7.3.2.3 Regulatory Framework
7.3.2.4 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Germany Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.3.2 Key Country Dynamics
7.3.3.3 Regulatory Framework
7.3.3.4 Reimbursement Scenario
7.3.4 Spain
7.3.4.1 Spain Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.4.2 Key Country Dynamics
7.3.4.3 Regulatory Framework
7.3.4.4 Reimbursement Scenario
7.3.5 France
7.3.5.1 France Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.5.2 Key Country Dynamics
7.3.5.3 Regulatory Framework
7.3.5.4 Reimbursement Scenario
7.3.6 Italy
7.3.6.1 Italy Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.6.2 Key Country Dynamics
7.3.6.3 Regulatory Framework
7.3.6.4 Reimbursement Scenario
7.3.7 Denmark
7.3.7.1 Denmark Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.7.2 Key Country Dynamics
7.3.7.3 Regulatory Framework
7.3.7.4 Reimbursement Scenario
7.3.8 Sweden
7.3.8.1 Sweden Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.8.2 Key Country Dynamics
7.3.8.3 Regulatory Framework
7.3.8.4 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Norway Neurological Biomarkers Market, 2018-2030 (USD Million)
7.3.9.2 Key Country Dynamics
7.3.9.3 Regulatory Framework
7.3.9.4 Reimbursement Scenario
7.4 Asia-Pacific
7.4.1 Asia-pacific Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.2.2 Key Country Dynamics
7.4.2.3 Regulatory Framework
7.4.2.4 Reimbursement Scenario
7.4.3 China
7.4.3.1 China Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.3.2 Key Country Dynamics
7.4.3.3 Regulatory Framework
7.4.3.4 Reimbursement Scenario
7.4.4 India
7.4.4.1 India Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.4.2 Key Country Dynamics
7.4.4.3 Regulatory Framework
7.4.4.4 Reimbursement Scenario
7.4.5 South Korea
7.4.5.1 South Korea Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.5.2 Key Country Dynamics
7.4.5.3 Regulatory Framework
7.4.5.4 Reimbursement Scenario
7.4.6 Thailand
7.4.6.1 Thailand Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.6.2 Key Country Dynamics
7.4.6.3 Regulatory Framework
7.4.6.4 Reimbursement Scenario
7.4.7 Australia
7.4.7.1 Australia Neurological Biomarkers Market, 2018-2030 (USD Million)
7.4.7.2 Key Country Dynamics
7.4.7.3 Regulatory Framework
7.4.7.4 Reimbursement Scenario
7.5 Latin America
7.5.1 Latin America Neurological Biomarkers Market, 2018-2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Neurological Biomarkers Market, 2018-2030 (USD Million)
7.5.2.2 Key Country Dynamics
7.5.2.3 Regulatory Framework
7.5.2.4 Reimbursement Scenario
7.5.3 Mexico
7.5.3.1 Mexico Neurological Biomarkers Market, 2018-2030 (USD Million)
7.5.3.2 Key Country Dynamics
7.5.3.3 Regulatory Framework
7.5.2.4 Reimbursement Scenario
7.5.4 Argentina
7.5.4.1 Argentina Neurological Biomarkers Market, 2018-2030 (USD Million)
7.5.4.2 Key Country Dynamics
7.5.4.3 Regulatory Framework
7.5.4.4 Reimbursement Scenario
7.6 MEA
7.6.1 MEA Neurological Biomarkers Market, 2018-2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Neurological Biomarkers Market, 2018-2030 (USD Million)
7.6.2.2 Key Country Dynamics
7.6.2.3 Regulatory Framework
7.6.2.4 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Neurological Biomarkers Market, 2018-2030 (USD Million)
7.6.3.2 Key Country Dynamics
7.6.3.3 Regulatory Framework
7.6.3.4 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 UAE Neurological Biomarkers Market, 2018-2030 (USD Million)
7.6.4.2 Key Country Dynamics
7.6.4.3 Regulatory Framework
7.6.2.4 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Kuwait Neurological Biomarkers Market, 2018-2030 (USD Million)
7.6.5.2 Key Country Dynamics
7.6.5.3 Regulatory Framework
7.6.5.4 Reimbursement Scenario
Chapter 8 Neurological Biomarkers Market: Competitive Analysis
8.1 Company Categorization
8.2 Strategy Mapping
8.2.1 New Product Launches
8.2.2 Partnerships
8.2.3 Acquisitions
8.2.4 Collaborations
8.2.5 Funding
8.3 Company Market Share Analysis, 2022
8.4 Company Profiles
8.4.1 Abbott
8.4.1.1 Company Overview
8.4.1.2 Financial Performance
8.4.1.3 Product Benchmarking
8.4.1.4 Strategic Initiatives
8.4.2 Johnson & Johnson Services, Inc.
8.4.2.1 Company Overview
8.4.2.2 Financial Performance
8.4.2.3 Product Benchmarking
8.4.2.4 Strategic Initiatives
8.4.3 Bio-rad Laboratories, Inc.
8.4.3.1 Company Overview
8.4.3.2 Financial Performance
8.4.3.3 Product Benchmarking
8.4.3.4 Strategic Initiatives
8.4.4 Alseres Pharmaceuticals, Inc.
8.4.4.1 Company Overview
8.4.4.2 Product Benchmarking
8.4.5 Banyan Biomarkers, Inc.
8.4.5.1 Company Overview
8.4.5.2 Product Benchmarking
8.4.5.3 Strategic Initiatives
8.4.6 Rules-based Medicine
8.4.6.1 Company Overview
8.4.6.2 Financial Performance
8.4.6.3 Product Benchmarking
8.4.6.4 Strategic Initiatives
8.4.7 Thermo Fisher Scientific, Inc.
8.4.7.1 Company Overview
8.4.7.2 Financial Performance
8.4.7.3 Product Benchmarking
8.4.7.4 Strategic Initiatives
8.4.8 Diagenic Asa
8.4.8.1 Company Overview
8.4.8.2 Product Benchmarking
8.4.9 Merck & Co., Inc.
8.4.9.1 Company Overview
8.4.9.2 Financial Performance
8.4.9.3 Product Benchmarking
8.4.9.4 Strategic Initiatives
8.4.10 Quanterix
8.4.10.1 Company Overview
8.4.10.2 Product Benchmarking
8.4.10.3 Strategic Initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 North America neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 3 North America neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 4 North America neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 5 U.S. neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 6 U.S. neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 7 U.S. neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 8 Canada neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 9 Canada neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 10 Canada neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 11 Europe neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 12 Europe neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 13 Europe neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 14 U.K. neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 15 U.K. neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 16 U.K. neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 17 Germany neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 18 Germany neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 19 Germany neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 20 France neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 21 France neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 22 France neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 23 Italy neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 24 Italy neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 25 Italy neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 26 Spain neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 27 Spain neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 28 Spain neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 29 Denmark neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 30 Denmark neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 31 Denmark neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 32 Sweden neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 33 Sweden neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 34 Sweden neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 35 Norway neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 36 Norway neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 37 Norway neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 38 Asia-Pacific neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 39 Asia-Pacific neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 40 Asia-Pacific neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 41 Japan neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 42 Japan neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 43 Japan neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 44 China neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 45 China neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 46 China neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 47 India neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 48 India neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 49 India neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 50 South Korea neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 51 South Korea neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 52 South Korea neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 53 Australia neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 54 Australia neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 55 Australia neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 56 Thailand neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 57 Thailand neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 58 Thailand neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 59 Latin America neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 60 Latin America neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 61 Latin America neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 62 Brazil neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 63 Brazil neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 64 Brazil neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 65 Mexico neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 66 Mexico neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 67 Mexico neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 68 Argentina neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 69 Argentina neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 70 Argentina neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 71 MEA neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 72 MEA neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 73 MEA neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 74 South Africa neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 75 South Africa neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 76 South Africa neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 77 Saudi Arabia neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 78 Saudi Arabia neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 79 Saudi Arabia neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 80 UAE neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 81 UAE neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 82 UAE neurological biomarkers market, by end-use, 2018-2030 (USD Million)
Table 83 Kuwait neurological biomarkers market, by application, 2018-2030 (USD Million)
Table 84 Kuwait neurological biomarkers market, by type, 2018-2030 (USD Million)
Table 85 Kuwait neurological biomarkers market, by end-use, 2018-2030 (USD Million)
List of Figures
Figure 1 Neurological biomarkers market segmentation
Figure 2 Market research process
Figure 3 Information procurement
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 QFD modeling for market share assessment
Figure 8 Market formulation & validation
Figure 9 Market snapshot
Figure 10 Segment snapshot (Type and application)
Figure 11 Segment snapshot (End-use)
Figure 12 Competitive landscape snapshot
Figure 13 Biomarkers market value, 2023 (USD Million)
Figure 14 Neurological biomarkers market dynamics
Figure 15 Prevalence of Alzheimer's disease by age group, 2023
Figure 16 Neurological biomarkers market: Porter’s Five Forces analysis
Figure 17 Neurological biomarkers market: PESTLE analysis
Figure 18 Neurological biomarkers market: Type outlook and key takeaways
Figure 19 Neurological biomarkers market: Type movement analysis
Figure 20 Genomic neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 21 Proteomic neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 22 Metabolomic neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 23 Imaging market estimates and forecast, 2018-2030 (USD Million)
Figure 24 Other neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 25 Neurological biomarkers market: Application outlook and key takeaways
Figure 26 Neurological biomarkers market: Application movement analysis
Figure 27 Alzheimer’s disease market estimates and forecast, 2018-2030 (USD Million)
Figure 28 Parkinson’s disease market estimates and forecast, 2018-2030 (USD Million)
Figure 29 Multiple sclerosis market estimates and forecast, 2018-2030 (USD Million)
Figure 30 Autism spectrum disorder market estimates and forecast, 2018-2030 (USD Million)
Figure 31 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 32 Neurological biomarkers market: End-use outlook and key takeaways
Figure 33 Neurological biomarkers market: End-use movement analysis
Figure 34 Hospitals & hospital laboratories market estimates and forecast, 2018-2030 (USD Million)
Figure 35 Independent clinical diagnostic centers market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Research organizations and others market estimates and forecast, 2018-2030 (USD Million)
Figure 37 Neurological biomarkers market revenue, by region, 2023 & 2030 (USD Million)
Figure 38 Regional marketplace: Key takeaways
Figure 39 North America market estimates and forecast, 2018-2030 (USD Million)
Figure 40 Key country dynamics
Figure 41 U.S. neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 42 Target disease prevalence
Figure 43 Key country dynamics
Figure 44 Canada neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 45 Target disease prevalence
Figure 46 Europe neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 47 Key country dynamics
Figure 48 UK neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 49 Key country dynamics
Figure 50 Germany neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 51 Target disease prevalence
Figure 52 Key country dynamics
Figure 53 France neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 54 Key country dynamics
Figure 55 Italy neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 56 Key country dynamics
Figure 57 Spain neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 58 Key country dynamics
Figure 59 Denmark neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 60 Key country dynamics
Figure 61 Sweden neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 62 Key country dynamics
Figure 63 Norway neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 64 Target disease prevalence
Figure 65 Rest of Europe market estimates and forecast, 2018-2030 (USD Million)
Figure 66 Asia-Pacific neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 67 Key country dynamics
Figure 68 Japan neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 69 Target disease prevalence
Figure 70 Key country dynamics
Figure 71 China neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 72 Key country dynamics
Figure 73 India neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 74 Target disease prevalence
Figure 75 Key country dynamics
Figure 76 Australia neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 77 Key country dynamics
Figure 78 Thailand neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 79 Key country dynamics
Figure 80 South Korea neurological biomarkers market estimates and forecast, 2018-2030 (USD Million)
Figure 81 Rest of Asia-Pacific market estimates and forecast, 2018-2030 (USD Million)
Figure 82 Latin America neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 83 Key country dynamics
Figure 84 Brazil neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 85 Key country dynamics
Figure 86 Mexico neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 87 Key country dynamics
Figure 88 Argentina neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 89 Rest of Latin America neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 90 MEA neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 91 Key country dynamics
Figure 92 South Africa neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 93 Target disease prevalence
Figure 94 Key country dynamics
Figure 95 Saudi Arabia neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 96 Target disease prevalence
Figure 97 Key country dynamics
Figure 98 UAE neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 99 Target disease prevalence
Figure 100 Key country dynamics
Figure 101 Kuwait neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 102 Target disease prevalence
Figure 103 Key payors in Kuwait
Figure 104 Rest of MEA neurological biomarkers market estimates and forecasts, 2018-2030 (USD Million)
Figure 105 Key company categorization
Figure 106 Company market positioning
Figure 107 Company market share analysis, 2023
Figure 108 Strategic framework

Companies Mentioned

  • ABBOTT
  • JOHNSON & JOHNSON SERVICES, INC.
  • BIO-RAD LABORATORIES, INC.
  • ALSERES PHARMACEUTICALS, INC.
  • BANYAN BIOMARKERS, INC.
  • RULES-BASED MEDICINE
  • THERMO FISHER SCIENTIFIC, INC.
  • DIAGENIC ASA
  • MERCK & CO., INC.
  • QUANTERIX

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedDecember 2023
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 8.05 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.75 Billion
Compound Annual Growth Rate12.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Neurological Biomarkers Market by Type, Application, End-user - Global Forecast 2025-2030 - Product Image

Neurological Biomarkers Market by Type, Application, End-user - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Neurological Biomarker Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Neurological Biomarker Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Neurological Biomarkers Market Report by Type, Application, End Use, and Region 2024-2032 - Product Image

Neurological Biomarkers Market Report by Type, Application, End Use, and Region 2024-2032

  • Report
  • 142 Pages
  • Global
From
Neurological Biomarkers for Alzheimer`S and Parkinson`S Diseases - Global Strategic Business Report - Product Image

Neurological Biomarkers for Alzheimer`S and Parkinson`S Diseases - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Neurological Biomarkers Global Market Report 2024 - Product Image

Neurological Biomarkers Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.